Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
OBJECTIVE
Graves' hyperthyroidism and antithyroid drugs empty the intrathyroid stores of hormones and iodine. The consequence is rapid 131I turnover and impending failure of radioiodine therapy. Can administration of additional inactive iodide improve 131I kinetics?


METHODS
Fifteen consecutive patients, in whom the 48 h post-therapeutically calculated thyroid dose was between 150 and 249 Gy due to an unexpectedly short half-life, received 3 x 200 microg inactive potassium-iodide (127I) daily for 3 days (Group A), while 17 consecutive patients with a thyroid dose of > or = 250 Gy (Group B) served as the non-iodide group. 48 hours after 131I administration (M1) and 4 or 5 days later (M2) the following parameters were compared: effective 131I half-life, thyroid dose, total T3, total T4, 131I-activity in the T3- and T4-RIAs.


RESULTS
In Group A, the effective 131I half-life M1 before iodine (3.81 +/- 0.93 days) was significantly (p < 0.01) shorter than the effective 131I half-life M2 (4.65 +/- 0.79 days). Effective 131I half-life M1 correlated with the benefit from inactive 127I (r = -0.79): Administration of 127I was beneficial in patients with an effective 131I half-life M1 of <3 or 4 days. Patients from Group A with high initial specific 131I activity of T3 and T4 showed lower specific 131I activity after addition of inactive iodine compared with patients from the same group with a lower initial specific 131I activity of T3 and T4 and compared with the patient group B who was given no additional inactive iodide. This correlation was mathematically described and reflected in the flatter gradient in Group A (y = 0.5195x + 0.8727 for 131I T3 and y = 1.0827x - 0.4444 for 131I T4) and steeper gradient for Group B (y = 0.6998x + 0.5417 for 131I T3 and y = 1.3191x - 0.2901 for 131I T4). Radioiodine therapy was successful in all 15 patients from Group A.


CONCLUSIONS
The administration of 600 microg inactive iodide for three days during radioiodine therapy in patients with Graves' hyperthyroidism and an unexpectedly short half-life of <3 or 4 days was a safe and effective alternative to the administration of a second radioiodine capsule.
Dietlein
M
M
Department of Nuclear Medicine, University of Cologne, 50924 Cologne, Germany. markus.dietlein@uni-koeln.de
Moka
D
D
Reinholz
U
U
Schmidt
M
M
Schomäcker
K
K
Schicha
H
H
Wellner
U
U
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000906:Antibodies / Q000097:blood; D003131:Combined Modality Therapy; D005260:Female; D006111:Graves Disease / Q000188:drug therapy / Q000532:radiotherapy*; D006801:Humans; D007453:Iodide Peroxidase / Q000276:immunology; D007454:Iodides / Q000008:administration & dosage / Q000627:therapeutic use*; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011989:Receptors, Thyrotropin / Q000097:blood; D012016:Reference Values; D013972:Thyrotropin / Q000097:blood; D014284:Triiodothyronine / Q000031:analogs & derivatives / Q000097:blood
D000906:Antibodies; D007454:Iodides; D007457:Iodine Radioisotopes; D011989:Receptors, Thyrotropin; D014284:Triiodothyronine; C040407:3,3',5-triiodothyronamine; D013972:Thyrotropin; D007453:Iodide Peroxidase